Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has proven to be successful against hematological malignancies. However, exploiting CAR T cells to treat solid tumors is more challenging for various reasons including the lack of suitable target antigens. Here, we identify the transmembrane...

Descripción completa

Detalles Bibliográficos
Autores principales: Hänsch, Lena, Peipp, Matthias, Mastall, Maximilian, Villars, Danielle, Myburgh, Renier, Silginer, Manuela, Weiss, Tobias, Gramatzki, Dorothee, Vasella, Flavio, Manz, Markus G, Weller, Michael, Roth, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628943/
https://www.ncbi.nlm.nih.gov/pubmed/37335916
http://dx.doi.org/10.1093/neuonc/noad108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628943/
https://www.ncbi.nlm.nih.gov/pubmed/37335916
http://dx.doi.org/10.1093/neuonc/noad108

Ejemplares similares